Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
155.00
+4.00 (2.65%)
Apr 28, 2026, 3:30 PM JST
Market Cap11.43B -35.3%
Revenue (ttm)n/a
Net Income-1.44B
EPS-20.64
Shares Out73.73M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume509,500
Average Volume852,675
Open149.00
Previous Close151.00
Day's Range149.00 - 155.00
52-Week Range98.00 - 243.00
Betan/a
RSI68.64
Earnings DateApr 14, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements